Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Hold on to your seat.. something big happening here!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(290)
•••
Comment by Moonshiner592on Jul 01, 2020 11:06am
142 Views
Post# 31212080

RE:RE:RE:RE:RE:Hold on to your seat.. something big happening here!

RE:RE:RE:RE:RE:Hold on to your seat.. something big happening here!
Looking4Doubles wrote:
Newinvestor68 wrote: There is nothing new. Same recycled message with nothing concrete 


Well, I saw a change !

First announcement said:   " Salzman Group will grant to Kalytera a license to commercialize R-107 for treatment of COVID-19 in Canada."

The latest one says: " Upon closing of the first part of the Acquisition Transaction, Kalytera will acquire from Salzman Group an exclusive, worldwide license to develop and commercialize R-107 for treatment of coronavirus and COVID-19 "


.. I too noted this change as well! .... was about to open the champagne .... but ... I've decided to wait ....those that 'read' the NR  also noted it - NewInvestor68 - did you even read the latest NR??

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities